Page 71 - CIBERSAM2016-ENG

Most relevant scientific articles
• Torres-Sanchez S, Perez-Caballero L, Berrocoso E. Cellular and molecular mechanisms triggered by Deep Brain Stimulation in depression: A preclinical and clinical approach.Progress in neuro- psychopharmacology & biological psychiatry. 2016.
• Bravo L., Mico J.A., Rey-Brea R., Camarena-Delgado C., Berrocoso E.. Effect of DSP4 and desipramine in the sensorial and affective component of neuropathic pain in rats. Progress in Neuro- Psychopharmacology and Biological Psychiatry. 2016; 70:57-67.
• Llorca-Torralba M, Borges G, Neto F, Mico JA, Berrocoso E. Noradrenergic Locus Coeruleus pathways in pain modulation.Neuroscience. 2016.
• MacDowell K.S., Caso J.R., Martin-Hernandez D., Moreno B.M., Madrigal J.L.M., Mico J.A. et al. The Atypical Antipsychotic Paliperidone Regulates Endogenous Antioxidant/Anti-Inflammatory Pathways in Rat Models of Acute and Chronic Restraint Stress. Neurotherapeutics. 2016:1-11.
• Kosek E., Cohen M., Baron R., Gebhart G.F., Mico J.-A., Rice A.S.C. et al. Do we need a third mechanistic descriptor for chronic pain states? Pain. 2016;157(7):1382-1386.
Hightlights
In 2016, our group has continued focussing on three of its main translational and collaborative lines with other CIBERSAM groups: 1) the molecular mechanisms involved in the mechanism of action of Deep Brain Stimulation (DBS); 2) the biochemical mechanisms involved in the comorbidity of mental disorders and chronic pain and 3) the implication of neuro-inflammatory mechanisms in schizophrenia. The
results obtained in these investigations have been published in journals situated in the first decile of JCR (Schizophrenia Bulletin, Cerebral Cortex, Pain). In relation to these investigations, specifically the line 2, we have obtained a Project of the Brain & Behavior Foundation (EEUU) as well as a project of the National Research Plan.
The key milestones may be summarized as follow: In relation to treatment-resistant depressions, we have demonstrated that AMPA receptor activation appears necessary and sufficient to elicit an antidepressant response with DBS.
In the line of schizophrenia, our group in collaboration with several CIBERSAM groups, has investigated whether potential changes in plasma levels of neurotrophins (BDNF and NGF) and their specific receptors, may act as potential biomarkers of risk and protective factors of schizophrenia. In the same vein, we have also participated, in collaboration with other CIBERSAM groups, in the demonstration that the increase of endogenous antioxidant / anti-inflammatory factors may be the basis of the mechanism of action of some of the current antipsychotics.
In the line of comorbidity mental disorders-chronic pain, our group in relation to other international groups, have proposed a new terminology in pain that allows to interpret the emotional symptoms in relation to the physical symptoms presents in patients.
Finally, our group has actively participated in the organization and scientific facts of the Master of Initiation to Research in Mental Health.
SAM
research groups 71